This review is a summary of a pooled analysis study; Five-year outcomes with dabrafenib plus trametinib in BRAF V600 positive metastatic melanoma: pooled analysis from the COMBI-d and COMBI-v trials. This study involved analysis of 5-year results of 563 patients.
Independent commentary is provided by Associate Professor Victoria Atkinson, Senior Staff Specialist Medical Oncologist at the Princess Alexandra Hospital, and Medical Oncologist at Greenslopes Private Hospital.
Please login below to download this issue (PDF)